139 related articles for article (PubMed ID: 22847535)
61. [Adjuvant drug therapies for breast cancer].
Huovinen R; Auvinen P; Mattson J; Joensuu H
Duodecim; 2015; 131(1):23-8. PubMed ID: 26245052
[TBL] [Abstract][Full Text] [Related]
62. Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.
Bulut N; Harputluoglu H; Dizdar O; Altundag K
J Neurooncol; 2008 Jan; 86(2):241. PubMed ID: 17612792
[No Abstract] [Full Text] [Related]
63. FDA expands us of herceptin for early-stage breast cancer.
Mayo Clin Womens Healthsource; 2007 Jun; 11(6):3. PubMed ID: 17476181
[No Abstract] [Full Text] [Related]
64. [Isolated effect of the monoclonal antibody trastuzumab (Herceptin) in a patient with local recurrence of breast carcinoma with HER-2 hyperexpression. ].
Del Giglio A
Rev Assoc Med Bras (1992); 2006; 52(4):202. PubMed ID: 16967134
[No Abstract] [Full Text] [Related]
65. [On strengthening the link between the basic medical sciences and clinical practice].
Bu H
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):3-4. PubMed ID: 20388390
[No Abstract] [Full Text] [Related]
66. HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
Iorfida M; Dellapasqua S; Bagnardi V; Cardillo A; Rotmensz N; Mastropasqua MG; Bottiglieri L; Goldhirsch A; Viale G; Colleoni M
Ann Oncol; 2012 May; 23(5):1371-1372. PubMed ID: 22412042
[No Abstract] [Full Text] [Related]
67. Increased HER2 with U.S. Food and Drug Administration-approved antibody.
Roche PC; Ingle JN
J Clin Oncol; 1999 Jan; 17(1):434. PubMed ID: 10458264
[No Abstract] [Full Text] [Related]
68. More than one way to look for HER2.
Check W
CAP Today; 1999 Mar; 13(3):1, 40-2, 46, passim. PubMed ID: 10350906
[No Abstract] [Full Text] [Related]
69. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab.
Platini C; Long J; Walter S
Lancet Oncol; 2006 Sep; 7(9):778-80. PubMed ID: 16945774
[No Abstract] [Full Text] [Related]
70. Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.
Di Cosimo S; Serpico D; Porcu L; Molino L; Fanetti G; Torri V; de Braud F
Clin Oncol (R Coll Radiol); 2014 Mar; 26(3):174. PubMed ID: 24368057
[No Abstract] [Full Text] [Related]
71. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.
Nazemalhosseini Mojarad E; Kuppen PJ
Immunotherapy; 2013 Dec; 5(12):1267-9. PubMed ID: 24283833
[No Abstract] [Full Text] [Related]
72. Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.
Chalasani P; Shtivelband MI; Cranmer LD
Clin Adv Hematol Oncol; 2009 Jul; 7(7):473-5. PubMed ID: 19701155
[No Abstract] [Full Text] [Related]
73. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
Tanizaki J; Tsurutani J
Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
[No Abstract] [Full Text] [Related]
74. Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.
McLaren EH
BMJ; 2005 Nov; 331(7526):1203. PubMed ID: 16293854
[No Abstract] [Full Text] [Related]
75. [New therapies lower risk of recurrence. Hope for healing in breast carcinoma? (interview by Dr. Judith Neumaier)].
von Minckwitz G
MMW Fortschr Med; 2005 Jul; 147(27-28):14. PubMed ID: 16041933
[No Abstract] [Full Text] [Related]
76. Recurrence of breast cancer in elderly women.
Serraino D; Berretta M; Tirelli U
J Clin Oncol; 2014 Jan; 32(2):161. PubMed ID: 24323029
[No Abstract] [Full Text] [Related]
77. [Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer].
; ;
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):315-9. PubMed ID: 23985265
[No Abstract] [Full Text] [Related]
78. Trastuzumab: qui bono?
Krop IE; Burstein HJ
J Natl Cancer Inst; 2013 Dec; 105(23):1772-5. PubMed ID: 24262439
[No Abstract] [Full Text] [Related]
79. Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy.
Savas P; Loi S
Immunotherapy; 2014; 6(7):803-5. PubMed ID: 25290412
[No Abstract] [Full Text] [Related]
80. Targeted Therapy and Local Control: The Dynamic Duo.
Mamtani A; King TA
Ann Surg Oncol; 2017 Oct; 24(11):3110-3112. PubMed ID: 28748442
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
